Trastuzumab trials for Breast cancer

All Trastuzumab trials · All Breast cancer trials

Phase breakdown

Recruiting trials studying Trastuzumab for Breast cancer

• A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
  NCT07102381 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 35 locations
• A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer
  NCT07441460 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer
  NCT06435429 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 166 locations
• A Study for the Adjuvant Treatment of Breast Cancer
  NCT05420467 · Phase: Phase 4 · Ages: 18 Years and older · Sex: Female · 1 location
• A Study for the Neoadjuvant Treatment of Breast Cancer
  NCT05420454 · Phase: Phase 4 · Ages: 18 Years and older · Sex: Female · 1 location
• A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or Metastatic Breast Cancer
  NCT07518173 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: Female · 2 locations
• A Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer
  NCT06891833 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 75 Years · Sex: Female · 30 locations
• A Study of DB-1310 in Advanced/Metastatic Solid Tumors
  NCT05785741 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 72 locations
• ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
  NCT07007559 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 54 locations
• An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+ Breast Cancer With Brain Metastasis
  NCT05376878 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• BRE-10: Biomarker Optimization of Neoadjuvant Therapy in Breast Cancer
  NCT06441890 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
  NCT06324357 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 105 locations
• Circulating Tumor Cells and Treatment De-escalation After Neoadjuvant Therapy for HER2 Positive Breast Cancer
  NCT04993014 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer
  NCT04329065 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial
  NCT06278870 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: Female · 1 location
• EC-THP Versus TCbHP in HER2-positive Lymph Node Positive Early Breast Cancer
  NCT05883852 · Phase: Phase 3 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer.
  NCT05838066 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Elacestrant in Advanced Triple Positive Breast Cancer
  NCT07612215 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Female · 1 location
• FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
  NCT07216105 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 5 locations
• Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
  NCT05582499 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer
  NCT07377643 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Neoadjuvant Trastuzumab, Pertuzumab and Tucatinib Without Chemotherapy in HER2-positive Breast Cancer: the TRAIN-4 Study
  NCT06162559 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Neoadjuvant Trastuzumab-rezetecan Plus Pertuzumab or Nab-Paclitaxel, Carboplatin, Trastuzumab, and Pyrotinib After Suboptimal Response to Neoadjuvant Dual HER2-Targeted Therapy Combined With Chemotherapy in HER2-Positive Early Breast Cancer
  NCT07340398 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: Female · 1 location
• Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
  NCT06625775 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 88 locations
• Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial
  NCT07407920 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Pre Operative Trastuzumab in Operable Breast Cancer
  NCT01785420 · Phase: Phase 3 · Ages: 18 Years to 80 Years · Sex: Female · 1 location
• Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast Cancer
  NCT05638594 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: Female · 1 location
• RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
  NCT07413939 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 186 locations
• SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC
  NCT06927180 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• Safety of Continuing HER-2 Directed Therapy in Overt Left Ventricular Dysfunction
  NCT04680442 · Phase: Phase 2 · Ages: No age limits stated · Sex: All (male and female) · 8 locations
• Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab
  NCT05325632 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
  NCT06686394 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 18 locations
• The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC).
  NCT06217185 · Phase: Phase 4 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer
  NCT05900206 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 7 locations
• Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers
  NCT04886531 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• Trial of Therapies With IT cDC1s Combined w/ IT Trastuzamab for Her+ or IT Nivolumab for Her- BC LMD
  NCT07694986 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Trilaciclib in Patients With Early-Stage HR-negative Breast Cancer Receiving Adjuvant Chemotherapy
  NCT05978648 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Tucatinib, Trastuzumab and Capecitabine With Brain and/or Spinal Radiotherapy (XRT) in Patients With HER2+, HER2 Mutated and/or HER2-amplified Metastatic Breast Cancer and Leptomeningeal Disease: A Multi-centre Phase II, Single Arm Feasibility Study
  NCT06016387 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• ctDNA in HER2+ EBC Neoadjuvant Treatment
  NCT07335081 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: Female · 1 location

Common questions

How many trials study Trastuzumab for Breast cancer?

39 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.